Samsung Biologics (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Samsung Biologics" in English language version.

refsWebsite

Global rank English rank

9fiercepharma.com

low place

8,921^st place

6koreaherald.com

463^rd place

348^th place

4koreatimes.co.kr

536^th place

386^th place

3bioprocessintl.com

low place

low place

314^th place

285^th place

2businesskorea.co.kr

low place

low place

low place

7,595^th place

low place

low place

1biopharma-reporter.com

low place

low place

1koreabiomed.com

low place

low place

1biopharminternational.com

low place

low place

low place

low place

low place

low place

49^th place

47^th place

1europeanpharmaceuticalreview.com

low place

low place

biopharma-reporter.com

biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.

biopharminternational.com

"Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II". BioPharm International. 21 March 2023.

bioprocessintl.com

Dan Stanton (16 June 2020). "Samsung Biologics selects San Francisco for first US facility". BioProcess International.
Stanton, Dan (23 November 2020). "Samsung Bio in $150m deal to make COVID antibodies for Lilly". BioProcess International.
Nelson, Millie (30 October 2023). "Samsung Biologics strikes manufacturing and development deal with Kurma". BioProcess International.

biospace.com

Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.
Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.

businesskorea.co.kr

"Samsung Biologics Surpasses 1 Trillion Won in Annual Operating Profit for 1st Time". BusinessKorea. 25 January 2024.
Choi, Jasmine (23 January 2024). "Samsung Biologics Achieves Top 'Platinum' Rating in EcoVadis ESG Evaluation". Business Korea.

europeanpharmaceuticalreview.com

Eckford, Catherine. "2022 Terra Carta Seal: three pharma companies awarded". European Pharmaceutical Review.

fiercepharma.com

Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
Liu, Angus (22 May 2020). "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma.
"Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma.
Keenan, Joseph (14 December 2021). "Samsung Biologics, AstraZeneca expand manufacturing partnership to add COVID and cancer therapies". Fierce Pharma.
Keenan, Joseph (7 February 2024). "Samsung Biologics, LegoChem partner to propel ADC development and production". Fierce Pharma.
Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.

joins.com

koreajoongangdaily.joins.com

Ha-Nee, Shin (7 June 2024). "Business soars for Korean pharma as U.S. cuts ties with Chinese partners". Korea JoongAny Daily.
"Samsung Biologics signs largest-ever $1.2 billion deal". Korea JoongAng. 2024.
"Samsung Bioepis's Opuviz gets EC approval". Korea JoongAng. 2024.

kedglobal.com

Ahn, Dae-Kyu (7 June 2024). "Samsung Biologics eyes windfall gain amid US-China row". The Korean Economic Daily.
"Samsung's Life Science Fund invests in US biotech Jaguar Gene Therapy". The Korea Economic Daily. 30 March 2022.

koreabiomed.com

"Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.

koreaherald.com

"Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
"Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald.
"Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
Jeong-yeo, Lim (5 August 2020). "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
"Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald.

koreatimes.co.kr

"Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
"Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
Byung-yeul, Baek (13 February 2024). "Samsung Biologics recognized for response to climate change". The Korea Times.

pharmtech.com

Thomas, Felicity (20 September 2023). "Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb". Pharmaceutical Technology.

pmlive.com

Tyler, Dominic (24 October 2013). "Roche signs biologics partnership with Samsung". PMLiVE.

reuters.com

Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.